Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Alessi

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Colorectal Cancer|December 17, 2016
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Urologic Oncology|October 19, 2020
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumabLaura Marandino, Antonella Capozza, Marco Bandini, et al.
European Urology Focus|November 11, 2020
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical CystectomyLaura Marandino, Antonella Capozza, Marco Bandini, et al.
Oncology|September 8, 2017
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET PredictionsRosa Berenato, Federica Morano, Filippo Pietrantonio, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Clinical Colorectal Cancer|December 19, 2018
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Christian Cotsoglou, Giovanni Fucà, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
Cancers|February 11, 2023
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid TumorsLaura Evangelista, Andrea Bianchi, Alessio Annovazzi, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 25, 2023
Can Baseline [<sup>18</sup>F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective StudyAndrea Bianchi, Maria Luisa De Rimini, Rosa Sciuto, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Colorectal Cancer|December 17, 2016
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Urologic Oncology|October 19, 2020
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumabLaura Marandino, Antonella Capozza, Marco Bandini, et al.
European Urology Focus|November 11, 2020
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical CystectomyLaura Marandino, Antonella Capozza, Marco Bandini, et al.
Oncology|September 8, 2017
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET PredictionsRosa Berenato, Federica Morano, Filippo Pietrantonio, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Clinical Colorectal Cancer|December 19, 2018
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Christian Cotsoglou, Giovanni Fucà, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
Cancers|February 11, 2023
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid TumorsLaura Evangelista, Andrea Bianchi, Alessio Annovazzi, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 25, 2023
Can Baseline [<sup>18</sup>F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective StudyAndrea Bianchi, Maria Luisa De Rimini, Rosa Sciuto, et al.
Pageof 3